Madrigal Pharmaceuticals’ Post

Discover the one with Labcorp's in vivo respiratory disease and PK/PD models. Learn how an integrated approach to discovery efficacy and early safety respiratory studies can yield the on-time, high-quality data you expect. With decades of experience and valuable insights, we’re dedicated to meeting your timelines. #RespiratoryDisease #InVitroAerosolSafety #Biomarkers #DiscoveryBioanalysis #Histology #Pathology #CRO #DrugDiscovery

Discover the one with Labcorp's in vivo respiratory disease and PK/PD models. Learn how an integrated approach to discovery efficacy and early safety respiratory studies can yield the on-time, high-quality data you expect. With decades of experience and valuable insights, we’re dedicated to meeting your timelines. #RespiratoryDisease #InVitroAerosolSafety #Biomarkers #DiscoveryBioanalysis #Histology #Pathology #CRO #DrugDiscovery

Study shows important role gut microbes play in airway health in persons with cystic fibrosis https://lnkd.in/gb_gBPfm

🤖 "AI: Towards an Integrative Clinical Care" at #EASLCongress 2024! Explore AI's role in liver disease management. Let's revolutionise hepatology together by understanding AI's potential and limitations in liver disease management & real-world settings. https://bit.ly/3UhxA5W

Correlation of Liver Elastography as a Predictor of Esophageal Varices and Its Comparison With Ultrasound Abdomen and Liver Function Tests in Patients With Chronic Liver Disease.

We applaud EASL's (European Association for the Study of the Liver) new nomenclature for NASH, which provides a more precise description of the underlying pathology of disease. Non-alcoholic steatohepatitis or NASH will now be known as metabolic dysfunction-associated steatohepatitis or MASH, making clear that metabolic dysfunction is the primary driver of the disease. #NASH to #MASH Read more: https://lnkd.in/d9ZsEjef

Endomyocardial Fibrosis (EMF): A Deep Dive into the Heart's Struggle "Ever wondered how a seemingly silent condition can significantly affect the heart's function? Today, we delve into the world of Endomyocardial Fibrosis. This is a disorder primarily located in tropical and subtropical regions. It's characterized by a type of heart disease known as restrictive cardiomyopathy and fibrotic changes in the endocardium, a layer that lines the interior of the heart. These changes are usually limited to the cardiac apex, the lower tip of the heart. Interesting, isn't it? Endomyocardial Fibrosis is often considered part of a disease spectrum that includes another condition called Löeffler endocarditis. So, we're dealing with a quite fascinating and complex health issue here. But don't fret, we'll unravel it together, one piece at a time. So, we've understood that Endomyocardial Fibrosis is a restrictive cardiomyopathy that brings about fibrotic changes in the heart. But how do we identify it?" "Endomyocardial Fibrosis is predominantly seen in specific regions. Let's delve into its epidemiology and incidence. This disorder is primarily found in tropical and subtropical regions, with a particular concentration in the equatorial belt. Africa, in fact, records the highest prevalence of this condition. The disease, however, is not limited to these areas and has made its presence known globally. The incidence rate, while not clearly defined, is significant enough to warrant attention. It's important to note that the prevalence and patterns of the disease can vary. Some regions have reported a decline in Endomyocardial Fibrosis cases. This decrease is possibly connected to improvements in healthcare systems and living standards, highlighting the impact of socio-economic factors on the disease's distribution. "We've covered a lot of ground today about Endomyocardial Fibrosis. We've learned that it's a condition primarily seen in tropical and subtropical regions, where the inner layers of the heart muscles undergo fibrosis, making the heart's job of pumping blood more challenging. We've discussed how it's diagnosed, its signs and symptoms, and its epidemiology. The incidence rate is highest in equatorial regions, particularly in Africa, and there's no significant gender bias. It's crucial to remember that despite advancements in healthcare, this condition has a significant impact on one's survival rate. Endomyocardial Fibrosis is a silent yet significant condition. By understanding it, we are one step closer to fighting it. Stay informed and stay healthy." Viral Keywords: 1. Restrictive Cardiomyopathy 2. Silent Heart Condition 3. Endomyocardial Fibrosis Awareness 4. Tropical Heart Disease 5. Fibrotic Cardiac Changes

Check our new review paper on how macrophage deals with dead cell in the pathogenesis of liver disease. https://lnkd.in/eRd5VgVP

Molecular basis of ClC-6 function and its impairment in human disease SCIENCE ADVANCES https://lnkd.in/gKisbk29

Trending on #ReadbyQxMD Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives - https://lnkd.in/g3-zqdNy From: International Journal of Environmental Research and Public Health #Lipoprotein #Cardiology